ketobemidone
Trade name: Ketogan
Ketobemidone, sold under the brand name Ketogan among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2017 (NCT03023462)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
- Kappa opioid receptorAGONIST
OPRK1 agonist
- Mu opioid receptorAGONIST
OPRM agonist
- Glutamate NMDA receptor; GRIN1/GRIN2AANTAGONIST
Glutamate NMDA receptor; GRIN1/GRIN2A antagonist
Chemistry & pharmacology
SMILES
CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1- Mol. weight
- 247.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaKetobemidone ↗
- ChEMBLCHEMBL47072 ↗
Also known as
- 1-(4-(3-hydroxyphenyl)-1- methyl-4-piperidinyl)-1-propanone
- 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-1-propanone
- cetobemidon
- cetobemidon
- cetobemidone
- cliradon
- cliradone
- ketobemidone
- ketobemidone
- ketobemidone
- ketobemidone
- ketobemidone
- ketobemidone
- ketobemidone
- ketobemidone hydrochloride
- ketobemidone hydrochloride
- ketobemidone hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03023462 | Phase 4 | Apr 1, 2017 | Ostfold University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ostfold University | Academic/Hospital | 1 | 1 | 1 | 2017 |